Neushen Therapeutics
Latest round
- Series B
Last raised
- Sep 2026
Total raised
- $80M
Investors
- 11
About Neushen Therapeutics
, trading under the name NeuShen Therapeutics, provides central nervous system (CNS) drug development solutions for the healthcare industry. The company was established to address major unmet clinical needs in the central nervous system through a dual platform of AAV gene therapy and small molecule innovation. The firm currently provides preclinical and clinical research candidates for conditions such as schizophrenia and Alzheimer's disease to the global pharmaceutical market. The Founder and CEO is Dr. Huaqiong Shen, who previously served as CEO of Days of The Biotechnology. Neushen Therapeutics focuses on the central nervous system (CNS) innovative drug development and has a dual platform for adenovirus-associated virus (AAV) gene therapy and small molecule drug therapy innovation, with AAV-based gene therapy and small molecule drug therapy innovation driving engine. AAV gene therapy platform enables the development of AAV-compatible microRNA scaffolds for effective and precise gene silencing. The company’s revenue is generated through strategic partnerships and licensing agreements for its proprietary drug candidates, and by developing therapeutic assets for future global commercialization within the central nervous system market.
Who invested in Neushen Therapeutics
11 investors across 3 rounds
See all investors in Neushen Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Neushen Therapeutics
Who invested in Neushen Therapeutics?
Neushen Therapeutics has 11 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neushen Therapeutics raised?
Neushen Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Neushen Therapeutics last raise money?
Neushen Therapeutics's most recent round on record is a Series B, in Sep 2026.
What does Neushen Therapeutics do?
, trading under the name NeuShen Therapeutics, provides central nervous system (CNS) drug development solutions for the healthcare industry.
Where is Neushen Therapeutics headquartered?
Neushen Therapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like Neushen Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Neushen Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Neushen Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.